Drawing for GENETHON BIOPROD

USPTO serial 79134009

GENETHON BIOPROD

Reviewed by CopyMark Law Group

Reg. 4545774Status 404
Filing date
Status date
Registration date
Jun 10, 2014
Examiner
WILSON, MARYNELLE WEST
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with GENETHON BIOPROD?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Janet G Ricciuti

Janet G Ricciuti JANET GILBERT RICCIUTI, PC1830 S Street, NWWashington, DC 20009UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical, veterinary and sanitary products, namely, gene and cell therapy products for the treatment of rare diseases; chemical preparations for medical and pharmaceutical use or for veterinary use, namely, gene and cell therapy products for the treatment of rare diseases; biological preparations for medical and pharmaceutical use or for veterinary use, namely, gene and cell therapy products for the treatment of rare diseases; enzyme preparations for medical and pharmaceutical use or for veterinary use; microorganism cultures for medical and pharmaceutical use or for veterinary use; culture media for bacteriology; nutritive substances for microorganisms for research and development of gene and cell therapy products used in the treatment of rare diseases; preparations of micro-organisms, of genetically modified organisms and of cells for medical and pharmaceutical use or for veterinary use, particularly for gene therapy and cell therapy; compounds acting on genetic or other pathologies, in human beings and animals, particularly on muscle and neuromuscular diseases, diseases of the immune system, cardiovascular diseases, dermatological diseases, diseases of the central and peripheral nervous system, cancers, asthma, allergies, lipid disorders, obesity and diabetes and infectious diseases; kits for preparing cells or for selecting biologically active compounds for medical, biomedical, chemical, genetic, pharmaceutical or veterinary use; diagnostic preparations, reagents and media for medical, biomedical, chemical, genetic, pharmaceutical or veterinary use; diagnostic reagents for in-vitro use in biochemistry, clinical chemistry and microbiology; sanitary preparations for medical useSECTION 71 - CANCELLED—
042Pharmaceutical research; research for the discovery of new medicines; scientific research, particularly in the medical, biomedical, chemical, genetic, pharmaceutical or veterinary fields; basic and applied research in the field of gene and cell therapy; technical research in the field of gene and cell therapy; sorting and selection of molecules for use in gene and cell therapy; development and validation of biological tests, cellular tests and genetic tests; activities in functional genomics for identifying, characterizing, validating or developing biologically active molecules; surveying engineering work; technical project study in the field of gene and cell therapy; professional consultancy unrelated to business operations in the field of scientific research and therapies; research and development of new pharmaceutical products for othersSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 17, 2023DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Dec 17, 2023DETHDEATH OF INTERNATIONAL REGISTRATION—
Dec 2, 2023INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Nov 14, 2023XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Nov 14, 2023XXCRGENERIC MADRID TRANSACTION CREATED—
Oct 26, 2021INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 26, 2021C71TCANCELLED SECTION 71—
Jun 10, 2019REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Dec 5, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Nov 4, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Nov 4, 2014FIMPFINAL DISPOSITION PROCESSED—
Sep 10, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 10, 2014R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 25, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 25, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 21, 2014GPNXNOTIFICATION PROCESSED BY IB—
Mar 5, 2014OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 5, 2014OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 5, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 19, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 19, 2014ALIEASSIGNED TO LIE—
Jan 31, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 31, 2014XAECEXAMINER'S AMENDMENT ENTERED—
Jan 31, 2014GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 31, 2014GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 31, 2014CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 16, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 16, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 16, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 18, 2013CRSNCORRECTION SENT TO IB—
Oct 18, 2013CRCRCORRECTION CREATED FOR IB—
Oct 8, 2013RFNTREFUSAL PROCESSED BY IB—
Sep 16, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 16, 2013RFRRREFUSAL PROCESSED BY MPU—
Sep 13, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 12, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 8, 2013DOCKASSIGNED TO EXAMINER—
Aug 16, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 12, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 8, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance